




RealRate

# PHARMACEUTICAL 2020

NovaBay Pharmaceuticals Inc.  
Rank 294 of 358





RealRate

# PHARMACEUTICAL 2020

## NovaBay Pharmaceuticals Inc. Rank 294 of 358



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 54% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -74%, being 111% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	9,381
Cost of Goods Sold	1,738
Intangible Assets	0
Liabilities, Current	5,687
Liabilities, Non-Current	505
Other Assets	1,729
Other Compr. Net Income	0
Other Expenses	8,024
Other Liabilities	4,055
Other Net Income	-1,001
Other Revenues	6,599
Property and Equipment	110
Research and Development	184
Selling, General and Administrative Expense	5,310

Output Variable	Value in 1000 USD
Assets	11,220
Liabilities	10,247
Expenses	15,256
Revenues	6,599
Stockholders Equity	973
Net Income	-9,658
Comprehensive Net Income	-9,658
Economic Capital Ratio	-74%